CD20-Immunotargeting in Metastatic Melanoma Patients- A Prospective, Open Label, Sequential Pilot Study

Trial Profile

CD20-Immunotargeting in Metastatic Melanoma Patients- A Prospective, Open Label, Sequential Pilot Study

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs Ofatumumab (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Jun 2011 New source identified and integrated (European Clinical Trials Database record EudraCT2010-023277-19).
    • 20 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top